Integris Medtech Limited is a diversified India-based global medical products and laboratory solutions company engaged in developing, manufacturing, commercialising and selling an integrated portfolio of medical devices and healthcare solutions. The company's business is primarily organised into two key segments: (i) Cardiovascular Devices, which includes drug-eluting stents, drug-coated balloons, complex coronary intervention products, wires, catheters and vascular access solutions; and (ii) Laboratory Solutions, comprising clinical diagnostics and scientific laboratory solutions for clinical, research and industrial laboratories.
The company operates manufacturing facilities in India, Germany and the Netherlands and also works with global manufacturers to support its extensive product portfolio. As of June 30, 2025, its medical devices and laboratory solutions were sold in more than 65 international markets outside India. According to the Frost & Sullivan industry report referenced in the DRHP, the company was the second-largest Indian-headquartered diversified medical technology platform in terms of operating revenue for Fiscal 2025.
Its cardiovascular product portfolio includes coronary stents, drug-coated balloons, coronary intervention products, wires and catheters, and other cardiovascular accessories. Its laboratory solutions business offers a broad range of clinical diagnostic products, scientific laboratory instruments, consumables and related solutions catering to hospitals, diagnostic laboratories, research institutions and industrial laboratories.
The company manages its operations across four principal geographical markets: India, Europe, Asia (excluding India) and the Rest of the World, comprising the Middle East, Africa and Latin America. Its international business is supported by an established network of subsidiaries, distributors and global manufacturing partners. In FY26, revenue from operations stood at ₹2,578.60 crore, with domestic operations contributing ₹736.35 crore and international operations contributing ₹1,842.25 crore.
The company's operations are supported by manufacturing and commercial infrastructure across multiple countries. Its manufacturing facilities in India, Germany and the Netherlands enable it to develop and supply medical devices, while its laboratory solutions business combines its own products with third-party products and distribution capabilities. The company also maintains a sales and distribution network serving healthcare professionals, hospitals, diagnostic laboratories, research institutions and industrial customers across its key markets.
The company focuses on expanding its medical technology portfolio through product development, innovation, manufacturing capabilities, strategic acquisitions and international market expansion. Its integrated business model combines cardiovascular devices, clinical diagnostics and scientific laboratory solutions, enabling it to serve multiple segments of the global healthcare and laboratory industries.
✍️ Post a Comment